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Javed N. Agrewala
We have recently demonstrated that Caerulomycin A induces regulatory T cells differentiation 
by suppressing Th1 cells activity. The role of regulatory T cells is well established in suppressing 
the function of Th2 cells. Th2 cells are known to inflict the induction of the activation of asthma. 
Consequently, in the present study, we monitored the influence of Caerulomycin A in inhibiting the 
activity of Th2 cells and its impact in recuperating asthma symptoms. Interestingly, we observed 
that Caerulomycin A significantly suppressed the differentiation of Th2 cells, as evidenced by 
downregulation in the GATA-3 expression. Further, decline in the levels of IL-4, IL-5 and IL-13 
cytokines and IgE was noted in the animals suffering from asthma. Furthermore, we noticed 
substantial suppression in the inflammatory response and number of eosinophils in the lungs. In 
essence, this study signifies an important therapeutic role of Caerulomycin A in asthma.
Asthma is a chronic pulmonary disease caused by inflammation of the airway mucosa and character-
ized by breathlessness and wheezing. Approximately 300 million people worldwide are suffering from 
asthma1. Recently, it has been reported that asthma incidents has considerably increased in the Western 
world2. It is estimated that 7% of US citizens suffer from asthma3. Thus, causing an increasing financial 
burden on health care services4.
The main cause of asthma is the dysregulated immune response towards harmless environmental anti-
gens. Airway remodelling, the reason behind the disease pathology of asthma is characterized by chronic 
inflammation of the airway, excessive mucus secretion and subepithelial fibrosis5. The airway mucosal 
system is a constitutive site exposed to microbes and non-microbial foreign substances. The immune 
system in the airway mucosa efficiently defends against pathogens. The homeostasis in mucosal surface 
is maintained by a delicate balance between pro- and anti-inflammatory conditions6. The disturbance in 
this balance results in airway hyper-responsiveness, which leads to allergy and asthma generation.
Although, underlying etiology behind the asthma pathogenesis is complex but Th2 cell is considered 
as a key player in the initiation, progression and persistence of asthma7. Th2 cell is a subset of CD4 T cells 
that mainly secretes IL-4 and IL-13 cytokines8. Despite the availability of numerous drugs, corticosteroids 
are most widely used for the treatment of asthma. Despondently, some individuals do not respond to 
the existing therapies9–10. Th2 response is known to induce glucocorticoid resistance11. Hence, patients 
suffering from severe asthma become unresponsive to the corticosteroids. Rise in asthma cases inflict 
huge economic burden on the healthcare related costs12. Consequently, there is an urgent need to search 
new therapeutic interventions that can inhibit Th2 cell response and eventually cures asthma.
Regulatory T cells (Tregs) are a subset of T helper cells. Tregs play a key role in the maintenance of 
immune homeostasis by controlling T cell-mediated immune response. There are increasing evidences 
that Tregs can actively suppress the activity of potentially harmful T cells13,14. Further, they have been 
implicated in antagonizing Th2 response and amelioration of allergic diseases15,16. Recently, we reported 
the induction of Tregs by Caerulomycin A (CaeA)17. Interestingly, the enhancement of Tregs adequately 
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regress the immunopathology caused by Th2 cells. Hence, for this reason wanted to evaluate the influ-
ence of CaeA in alleviating asthma. Interestingly, we observed that CaeA significantly suppresses Th2 
response and significantly attenuated asthma symptoms.
Materials and Methods
Chemicals and reagents. All cytokines and Abs used in ELISA and flowcytometry were pro-
cured from BD Biosciences (Franklin Lakes, NJ). FCS and RPMI-1640 were procured from Invitrogen 
(Carlsbad, CA). L-glutamine, L-pyruvate, penicillin, concanavalin A and streptomycin were from 
Serva (Heidelberg, Germany). Media components were purchased from Hi-media (Mumbai, India). 
Caerulomycin A was either procured from LKT Laboratories (St. Paul, MN) or was from actinomycetes, 
as described elsewhere18.
Mice. Female BALB/c and C3H/HeJ mice (6–8 wk) were procured from the experimental animal 
facility of the Institute of Microbial Technology. All experiments were reviewed and permitted by the 
Institutional Animal Ethical Committee and were carried out in accordance with the approved guidelines.
Differentiation of Th2 cells. Naïve CD4 T cells were purified by magnetic activated cell sorting 
(MACS). The isolated naïve T cells were highly purified and devoid of non-CD4 T cell population as 
ascertained by flowcytometry. Purity of naïve CD4 T cells obtained was 96% and devoid of CD8+ (CD8 
T cells), B220+ (B cells), F4/80+ (macrophages) and CD11c+ (dendritic cells) cells population as ascer-
tained by surface staining with their respective fluorochrome-tagged Abs and monitored through flow-
cytometry. Naïve CD4 T cells (2 × 105) were stimulated with plate bound anti-CD3 (1 μ g/ml) and soluble 
CD28 (2 μ g/ml) Abs. The cells were cultured under Th2 polarizing conditions (IL-4: 20 ng/ml, IL-2: 
100 U/ml, anti-IFN-γ Ab: 5 μ g/ml) for 4d at 37 °C/5% CO2. The cultures were replenished with polariz-
ing medium for additional 2d. Before harvesting, cells were treated with PMA (40 nM) and ionomycin 
(1 μ M) for 2 h. Later, cultures were treated with brefeldinA (10 μ g/ml) for 3 h to block cytokine secretion. 
CaeA was present in the cultures from the initiation of the experiments. The percentage of Th2 cells was 
enumerated by intracellular expression of IL-4 and GATA-3 by flowcytometry.
Flowcytometric analysis of T cells. The cells were washed in FACS buffer (PBS containing 1% FBS) 
twice after harvesting on final day. For surface staining of CD4 T cells, cells were suspended in FACS 
buffer containing pacific blue-anti-CD4 Abs (100 μ l) and incubated at 4 °C/30 min in dark. The cells were 
washed twice with FACS buffer and fixed in paraformaldehyde (4% ) 200 μ l for 4 °C/10 min in dark. The 
cells were washed with FACS buffer twice. Pelleted cells were resuspended in 200 μ l of saponin (0.5%) 
in PBS for permeabilization. The cells were incubated at RT/15 min in dark. The cells were pelleted 
and suspended in 50 μ l of saponin (0.5% saponin in PBS) containing PE-conjugated anti-GATA-3 and 
PE/Cy7-labelled anti-IL-4 Abs for 1 h/RT in dark. Later, cells were washed once with saponin. Finally, 
cells were washed with FACS buffer twice and re-suspended in 300 μ l of FACS buffer and acquired in 
FACSAria and analysed using FACSDiva software.
Experimental model of asthma. The asthma was induced as mentioned elsewhere18 with minor 
modifications. Briefly, mice were sensitized intraperitoneally (i.p.) with OVA (20 μ g) emulsified in alum 
(4 mg alum) in PBS (100 μ l). Booster dose was administered on 12d. Thirteen day onwards, mice were 
administered CaeA (1, 10 mg/kg bwt) and dexamethasone (Dex) (10 mg/kg bwt) for 12d (13d to 24d) 
through oral gavage. The animals were aerosol challenged daily with OVA (2%) for 20 min for last 6d (i.e. 
18d to 23d). On the final day (24d), the animals were aerosol challenged with OVA for 2 h. After 48 h 
of last challenge, mice were sacrificed. The severity of asthma was demonstrated by lung histopathology 
and levels of IL-5 and IL-13 and eosinophils in the BAL and lung cells.
Enumeration of eosinophils in the BAL. Eosinophils were enumerated as reported elsewhere19. 
Briefly, cells (2 × 106) were incubated with the anti-CD16 Ab to block the Fc receptor in staining 
buffer (1× PBS supplemented with 2% FBS) for 15 min/4 °C. The cells were washed and incubated 
with anti-CD11b and siglec-F Abs for 15 min/4 °C. Later, cells were washed and resuspended in fixative 
buffer (1× PBS + 1% paraformaldehyde). The samples were acquired using FACSAria and analysed by 
FACSDiva software.
Isolation of lung lymphocytes. Mice were euthanized with anaesthesia (100 mg/kg, sodium pento-
barbital, i.p.). The lungs of the animals were perfused through the right ventricle with chilled PBS till they 
turned white. Later, they were minced and incubated with digestion mixture (collagenase: 1 mg/ml) at 
37 °C/30 min. Digested tissues were disrupted with the help of syringe plunger and passed through 70 μ m 
pore size nylon cell strainers. The residual RBCs were lysed by ACK lysis buffer. The resultant single 
cell suspension was washed 3× with ice cold PBS. Cell number was counted by trypan blue exclusion 
method. These cells were in vitro challenged with OVA to monitor Th2 response.
Estimation of IgE. Total IgE in the BALF was estimated by sandwich ELISA. Briefly, 96w plates were 
coated (50 µl/well) with anti-IgE Abs in bicarbonate buffer (pH 9.6) and incubated for 12 h/4 °C. Later, 
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the plates were blocked with BSA (1%, 100 µl/well). ELISA plates were incubated with SNs (50 µl/well) 
and standard IgE (40–2000 pg/ml) for 12 h/4 °C. These plates were treated with their corresponding biotin 
conjugated secondary Abs, followed by streptavidin-HRP. Plates were developed using substrate H2O2 
and chromogenic agent OPD (o-phenylenediamine). The reaction was stopped by mixing equal volume 
of H2SO4 (7%). Optical density (OD) of the colour developed was measured at 495 nm. Usual steps of 
incubations and washings with PBS/Tween-20 (0.05%) were followed at each step. The level of Ab was 
estimated by plotting standard curve using IgE. Values are expressed as ng/ml. The similar procedure 
was followed for measuring OVA specific IgE in the BALF using appropriate reagents. Ninety-six well 
plates were coated with OVA (50 μ g/ml) followed by incubation with serum, anti-IgE-biotinylated Abs, 
streptavidin-HRP and OPD. Regular steps of washing were followed after incubation.
Estimation of cytokines. The IL-4, IL-5 and IL-13 were determined in the culture SNs and BAL fluid 
by ELISA, according to the manufacturer’s instruction (BD Bioscience, Franklin Lakes, NJ). Briefly, 96w 
microtitre plates were coated with respective Abs against IL-4, IL-5 or IL-13 in phosphate buffer (pH-9) 
for 12 h/4 °C. Later, the plates were blocked with BSA (1%) to eliminate nonspecific binding. The plates 
were incubated with SNs and appropriate cytokines standard for 12 h/4 °C. The plates were treated with 
respective biotin conjugated secondary Abs, followed by streptavidin-HRP. The colour was developed with 
the help of substrate H2O2 and chromogenic agent OPD. OD of the colour developed was measured at 
495 nm. Each step was followed by 5 times washing with 1× PBS-Tween20 (0.05%). The cytokine levels 
were estimated by plotting standard curve using recombinant cytokines and results expressed as pg/ml.
Estimation of cytokines by Real-Time PCR. RNA from the lung samples was isolated using TRIzol 
reagent, according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA). RNA was reverse tran-
scribed to cDNA with the help of synthesis kit (Fisher Scientific, Pittsburgh, PA). cDNA was analysed 
for the expression of IL-5 and IL-13 by Quantifast SYBR Green PCR kit (Qiagen, Hilden, Germany) 
employing Realplex master cycler (Eppendorf, Hamburg, Germany).
IL-5
Fwd – 5′ -AGCACAGTGGTGAAAGAGACCTT-3′ ,
Rev 5′ -TCCAATGCATAGCTGGTGAT-TT-3′ 
IL-13
Fwd – 5′ -GGAGCTGAGCAACATCACACA-3′ ,
Rev 5′ -GGTCCTGTAGATGGCATTGCA-3′ 
β -actin
Fwd 5′ -AGAGGGAAATCGTGCGTGAC-3′ ,
Rev 5′ -CAATAGTGATGACCTGGCCGT-3′ 
Ct values of experimental samples were normalized against β -actin, and analysis was done by com-
parative Ct method. Results are represented as relative expression (fold).
In vivo FMT tomographic imaging of animals suffering from asthma. The imaging of animals 
was performed as described elsewhere20. Briefly, animals were injected ProSense 750Ex i.v. under gas 
anaesthesia (isoflurane), 24 h prior to imaging. Fur of the animals was removed using hair clipper and 
depilatory cream to minimize the background interference. The anesthetized animals were carefully 
placed in the imaging cassette, followed by transfer into the chamber in FMT 2500Lx (PerkinElmer Life 
Sciences, Waltham, MA) in such a position that the lower abdomen faced CCD camera to give maximum 
resolution. The animals were excited by appropriate laser and the emitted fluorescence was measured. 
The amount of fluorescence generated was converted and represented as counts, which were directly 
proportional to pulmonary inflammation. Image processing and analysis was performed by TrueQuant 
software.
Histopathology. The lungs were fixed in buffered formalin (10%). Microtome sections of 
paraffin-embedded lungs were stained with either hematoxylin and eosin (H&E) or periodic acid-Schiff 
(PAS). To grade the extent of lung inflammation and goblet cell hyperplasia semiquatitative scoring sys-
tem was used as previously described21,22. Briefly, to score the inflammatory cell infiltration, cell counts 
were performed blind based on five point grading system for the following features: 0: normal, 1: few 
cells, 2: a ring of inflammatory cells 1 cell layer deep; 3: a ring of inflammatory cells 2–4 cells deep, 4: a 
ring of inflammatory cells of > 4 cells deep. Five fields were counted for each slide and mean score was 
calculated from five animals. For the quantification of goblet cells in the airway, five point grading system 
was used, 0: < 0.5% PAS positive cells, 1: < 25%, 2: 25–50%, 3: 50–75% and 4: > 75%. Eight fields were 
counted for each slide and mean score was calculated from 3 animals.
Statistical analysis. Statistical analysis was performed with the help of GraphPad Prism software. 
The difference between groups was compared by using two tailed Unpaired Student’s t-test.
Results
CaeA inhibits Th2 differentiation by suppressing the GATA-3 expression. IL-4 has been attrib-
uted for the differentiation of Th2 cells23. Hence, presence of IL-4 is a deciding factor for the generation 
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of Th2 response. The expression of transcription factor GATA-3 is selective for Th2 cells and plays crucial 
role in the differentiation of naïve CD4 T cells to Th2 cells24. Interestingly, we observed inhibition in the 
intracellular expression of IL-4 in terminally differentiated Th2 cells on treatment with CaeA (Fig. 1A). 
Similarly, it was noted that naïve CD4 T cells cultured with CaeA under Th2 polarizing conditions also 
showed significant (p < 0.0005) decrease in the number of IL-4+ CD4 T cells (Fig.  1B). Further, these 
cells also demonstrated substantial (p < 0.0005) downregulation in the expression of GATA-3 in IL-4+ 
CD4 T cells with CaeA treatment (Fig. 1C). These data signify that CaeA suppresses not only polarized 
Th2 cells but also differentiation of naïve CD4 T cells to Th2 cells by inhibiting the expression of Th2 
transcription factor GATA-3.
CaeA ameliorates the severity of asthma. Earlier, we have shown that CaeA can inhibit the secre-
tion of IL-5, a cytokine released by Th2 cells25. Th2 cells play a pivotal role in the progression of asthma26. 
Therefore, we hypothesize that treatment with CaeA may attenuate asthma symptoms. Consequently, 
we next examined in vivo effect of CaeA on the OVA induced experimental model of asthma using 
whole body imager. The fluorescent molecular tomography data very categorically showed substantially 
lesser disease symptoms in CaeA treated animals than the untreated controls (Fig.  2A). The disease 
severity and inflammation was measured by cathepsin specific reporter probe ProSense 750. Being a 
protease-activatable, pan-cathepsin fluorescent in vivo imaging agent, it is activated by key disease associ-
ated proteases such as cathepsin B, L, S, K, V and D. In this case, cathepsin D, secreted by the eosinophils 
present in lysosomal granules20. Later, ex vivo tissue fluorescent reflectance imaging was performed to 
authenticate the specificity of the signal that originated from the lungs. Excised lungs from the diseased 
mice showed widespread fluorescence throughout the organ (Fig. 2B). In contrast, CaeA treated animals 
showed significantly (p < 0.005) lesser fluorescence intensity with the increased dose (Fig. 2B,C). These 
results were comparable with the positive control group of animals treated with dexamethasone; the drug 
Figure 1. CaeA suppresses Th2 response. (A) Th2 cells or (B,C) naïve CD4 T cells differentiated under 
Th2 polarizing conditions were treated with CaeA (0–0.31 μ M). The cells were analyzed for the intracellular 
expression of (A,B) IL-4; (C) IL-4 and GATA3 on CD4 T cells by flowcytometry. (A) The data in the inset 
of flowcytometer histograms depicts percentage of cells from 3 independent experiments. (B,C) The data is 
representative of 3 independent experiments and mean ± SEM in the inset of flowcytometer histograms and 
dot plots depicts percentage of cells from duplicate wells. Bar diagram are representative of flowcytometry 
data. ***p < 0.0005.
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that is used to treat patients suffering from asthma. These data indicate that CaeA treatment effectively 
suppresses the asthma symptoms.
CaeA suppresses airway inflammation and eosinophil counts. To further substantiate our find-
ings illustrated in Fig. 2 and to show its biological significance, we conducted lung histopathology. The 
microscopic images depicted that the inflammatory response considerably decreased with the increas-
ing dose of CaeA. The lung sections of diseased animals clearly represented augmented infiltration of 
immune cells. Whereas, CaeA treated animals exhibited less infiltration (Fig. 3A). To support the above 
data, PAS staining of the sections was conducted to examine the goblet cell hyperplasia in the lung tissue. 
We distinctively observed decline in the extent of mucus secretion and number of mucus secreting cells 
on CaeA treatment (Fig. 3B). The observations were further confirmed by semiquantitative scoring of the 
inflammatory cells infiltration and PAS positive cells showing significant reduction in the airway inflam-
mation (p < 0.05) and goblet cell hyperplasia (p < 0.005) on treating with CaeA, as compared to diseased 
animals without treatment (Fig.  3C,D). We also analyzed the amount of inflammation by computing 
the total cell number in BAL fluid. The result shows that CaeA treated animal exhibited significantly 
(p < 0.005) lesser number of cells in the BAL fluid (Fig. 4A). As observed earlier, CaeA could regress the 
severity of disease symptoms indicated by lesser fluorescence intensity measured by FMT (Fig.  2A,B). 
Infiltration of eosinophils is a characteristic feature of asthma27. Hence, we examined the anti-asthmatic 
effect of CaeA by enumerating the eosinophils in the BAL fluid. The data showed that the percentage of 
Figure 2. CaeA ameliorates allergic asthma severity. Allergic asthma induced mice were treated with 
CaeA1 (1 mg/kg bwt) and CaeA10 (10 mg/kg bwt). Animals suffering from asthma receiving Dex10 (10 mg/
kg bwt) were kept as a positive control. A placebo (PBS) administered control groups were also kept of 
either normal mice or suffering from asthma. The disease severity was monitored by measuring lung 
inflammation. (A) Fluorescent tomographic imaging of animals probed with ProSense 750, represents a 
decrease in disease severity with CaeA and Dex treatment; (B) fluorescent reflectance imaging of excised 
lungs show decreased inflammation by CaeA; (C) bar diagram depict decrease in cathepsin activity as 
measured by ProSense 750 reporter probe. The colour bar on the right side indicates the severity of disease. 
The data are representative of 3 independent experiments and each bar represents means ± SEM of 6 mice 
per group. **p < 0.005.
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eosinophils in CaeA treated animals was significantly lower (p < 0.05) than that of diseased animals and 
corresponded to animals treated with dexamethasone (Fig. 4B,C). These observations are consistent with 
in vivo imaging results using FMT. Together, these data affirms prominent reduction in the inflammation 
in lungs on treating with CaeA.
Animals suffering from asthma on treatment with CaeA exhibited significant inhibition in 
the Th2 response. Th2 cells play a fundamental part in the pathogenesis of asthma. Upregulation of 
Th2 cytokines is the characteristic feature of allergic asthma28. Neutralization of Th2 cytokines IL-4, IL-5 
and IL-13 leads to decrease in the disease symptoms29–31. Hence to substantiate our results that CaeA 
diminishes disease symptoms (Fig. 4), we demonstrated that CaeA treatment significantly suppressed the 
Th2 response, in the animals suffering from asthma, as evidence by decreased levels of IL-5 and IL-13 
expression in both BAL fluid (Fig. 5A,B) and lung tissues (Fig. 5C,D), as compared to untreated group. 
The decrease in the cytokines level correlated with the increase in the dose of CaeA. The animals fed 
with a dose of 10 mg/kg bwt of either CaeA or Dex, expressed nearly same results.
Th2 cells promote the generation of IgE. Elevated level of IgE is an established hallmark for asthma 
progression. Intriguingly, there was substantial (p < 0.001) decline in the level of total and OVA specific 
Figure 3. Histology of lung sections. Allergic asthma induced mice were treated with CaeA1 (1 mg/kg bwt) 
and CaeA10 (10 mg/kg bwt). Animals suffering from asthma receiving Dex10 (10 mg/kg bwt) were kept as 
a positive control. The experimental and control groups of mice were sacrificed and the lungs were isolated 
and fixed in formalin solution. Representative microscopic photographs of sections were stained with (A) 
hematoxylin and eosin for the inflammatory cell infiltration analysis and (B) periodic acid-Schiff for the 
quantification of goblet cells. (A) Images of lung sections, the arrows denote decrease cellular infiltration by 
CaeA and Dex. (B) Image of lung section shows decrement in number and extent of goblet cell hyperplasia 
on CaeA and Dex treatment. Bar graph represents semi quantitative scoring of (C) inflammatory cell 
infiltration (mean ± SEM scores were obtained from 5 animals) and (D) PAS positive cells (mean± SEM 
scores were obtained from 3 animals). *p < 0.05, **p < 0.005.
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IgE (Fig. 5E,F). Furthermore, we also observed decrease in the yield of IL-4, IL-5 (p < 0.01) and IL-13 
(p < 0.05) released by splenic lymphocytes upon in vitro exposure to OVA (Fig. 5G–I). These data cate-
gorically signify that CaeA ameliorates asthma severity by suppressing Th2 response.
Discussion
Asthma is an inflammatory disease characterized by airway constriction and hyper reactivity to various 
allergens. Th2 cells orchestrate the development and progression of allergic asthma25,32. Th2 cells produce 
mainly IL-4, IL-5, and IL-13. These cytokines play an important role in the activation of eosinophils 
and mast cells and elevate the levels of IgE Abs33,34. IL-4 is responsible for isotype class switching of B 
lymphocytes to produce IgE35. In addition, it stimulates the expression of mucin and eotaxim by fibro-
blasts36,37. These factors contribute to the pathogenesis of asthma. Therefore, suppressing Th2 response is 
a worthy remedy for controlling asthma. Consequently, we started the current study since our prelimi-
nary experiments suggested that CaeA can efficiently suppress the Th2 response19. Further, many patients 
suffering from asthma either does not respond to the existing drugs or become refractory to them9–10. 
Accordingly, to overcome this problem, it becomes an urgent need to discover newer drugs.
Keeping in view of above mentioned facts, we studied the role of CaeA in animals suffering from 
asthma. Following major findings showed that CaeA significantly ameliorated the disease symptoms as 
evidenced by (i) decline in the inflammation, as observed through fluorescent molecular tomography 
by in vivo imaging of the mice; (ii) diminution in the lung pathology by histopathological analysis; 
(iii) reduced levels of Th2 cells and related cytokines IL-4, IL-5, IL-13; (iv) decrease in the IgE and 
Figure 4. CaeA suppresses the pool of eosinophils in asthma. The asthma induced mice were treated 
with CaeA and analyzed for cellular infiltration and eosinophil percentage in BAL fluid. (A) Dot plot 
describes the total cell counts, which signify decrease in cellular infiltration by CaeA. Each dot symbolises 
single mouse and data are represented as mean ± SEM; (B) flowcytometry contours depict decrease in 
the percentage of eosinophils in the BAL fluid of mice treated with CaeA. Value in the inset indicates 
percentage of eosinophils; (C) bar diagram denotes decrease in the percentage of eosinophils by CaeA. Error 
bar denotes mean ± SEM. Dex was taken as a positive control. The results shown are representative of 3 
independent experiments and each bar represents means ± SEM of 6 mice per group. *p < 0.05, **p < 0.005.
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eosinophils; (v) downregulation in the expression of GATA-3, confirming the authenticity of the CaeA 
action on Th2 cells.
Airway inflammation has been widely demonstrated in asthma individuals, and an association between 
the extent of inflammation and the disease severity has been reported38. When an asthma patient inhales 
allergen, it leads to an early allergic inflammatory response39,40. Interestingly, we noticed that CaeA treat-
ment significantly attenuated the inflammatory response in the mice suffering from asthma. Further, the 
total number of cells infiltrated into the BAL was also reduced.
Infiltration of eosinophil is a characteristic feature of asthma. IL-5 secreted by Th2 cells play a critical 
role in the differentiation, maturation and recruitment of eosinophils27,41. IL-5 is also responsible for the 
release of chemical mediators (superoxides) from the eosinophils42. Therefore, IL-5 has been implicated 
in the disease pathogenesis and makes it to be a crucial target for treating allergic diseases43. On the 
other hand, IL-13 plays an important role in the smooth muscle hyperplasia and subepithelial fibrosis44. 
Presence of Th2 cytokines in BAL fluid and bronchial submucosa can be observed in asthma individ-
uals45–47. Intriguingly, we observed that asthma mice treated with CaeA exhibited significant reduction 
in IL-5 and IL-13 levels in the BALF, as well as in the lungs. Further, infiltration of eosinophils in the 
lungs was also reduced, as was clearly depicted in decrease in fluorescence intensity and histopatholog-
ical analysis of the lungs. We considered that this effect is due to CaeA mediated inhibition of IL-5 and 
IL-13 in the lungs. The elevated levels of IgE against allergen is a biomarker of asthma48. CaeA treatment 
suppressed the IgE levels in asthma animals. Our studies on ex vivo antigen challenged total lung cells 
Figure 5. CaeA treated asthma mice exhibit downregulation of Th2 response. Allergic asthma induced 
mice were treated with CaeA1 (1 mg/kg bwt) and CaeA10 (10 mg/kg bwt). Animals suffering from asthma 
receiving Dex10 (10 mg/kg bwt) were kept as a positive control. A placebo (PBS) administered control 
groups were also kept of either normal mice or suffering from asthma. The animals were sacrificed and 
Th2 response was monitored. (A,B) Bar diagram depicts the reduced levels of IL-5 and IL-13 by ELISA in 
the BALF; (C,D) RT-qPCR data support the decreased expression of IL-5 and IL-13 in lungs; (E) dot plots 
represent decline in total IgE in BALF; each dot denotes a single mouse; (F) antigen specific IgE content 
in BALF; (G–I) ELISA data show diminished production of IL-4, IL-5 and IL-13 by lymphocytes in the 
SNs on in vitro challenged with OVA. Error bar represents mean ± SEM. The results shown are from 2–3 
independent experiments and each bar represents means ± SEM of 6 mice per group. nd: not detected. 
*p < 0.05, **p < 0.005, ***p < 0.0001.
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also showed decreased expression of IL-4, IL-5 and IL-13. Furthermore, we also established that CaeA 
not only inhibits the differentiated Th2 cells but also suppresses the naïve T cells from differentiating into 
Th2 cells. These results very categorically confirm that CaeA eases the asthma severity by suppressing 
Th2 response. Although, an acute and chronic form of asthma follows similar effector pathway, efficiency 
of CaeA has yet to be tested in regressing chronic asthma.
The expression of GATA-3 is a hallmark for the Th2 cell lineage24. It is fundamental in the exhibition 
of Th2 cytokines49. Hence, it was necessary for us to substantiate our data of suppression of Th2 response 
by CaeA by monitoring the expression of GATA-3. Interestingly, we noted remarkable downregulation 
in the expression of GATA-3 in the Th2 cells treated with CaeA. Thus, emphatically establishing the 
inhibitory role of CaeA on Th2 cells.
In essence, our study indicates that CaeA exhibits anti-asthmatic activity by suppressing inflammatory 
response in the lungs. This reduction was due to suppression of Th2 response in airway mucosal system. 
Finally, these results suggest potential role of CaeA in future for the treatment of allergic asthma.
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